I Got Denied or Downcoded

Active Motion Management Documentation

To avoid unnecessary denials for CPT 77412 when using active motion management, documentation should contain at least one of the following elements:

1. Medical necessity for motion management.
2. Real-time monitoring or gating system used: Identify the specific system or technology used for intrafraction motion tracking.
3. Workflow or parameters used for active motion management: Describe how motion is monitored during treatment, including thresholds, tolerance levels, and patient-specific setup.
4. Description of respiratory monitoring and tracking during treatment: Clarify whether monitoring is continuous, how motion data is acquired, and how the therapist is alerted to deviations.
5. Methodology determining beam‑on and beam‑off: State the criteria used to gate delivery, including what triggers beam-off events.

Examples of verbiage ASTRO physicians are using in their notes are below. Documentation can be templated or inserted into the consult note or sim order directly, but it should be clear and identifiable.

"DIBH is a form of active motion management where align RT is used during simulation to visually know when the breath is sufficient to move the heart further from the radiation field as per the NEJM article (Risk of ischemic heart disease in women after radiotherapy for breast cancer. Darby SC, et al. N Engl J Med. 2013 Mar 14;368(11):987-98. PMID: 23484825) distance from field leads to lower dose and less risk of heart disease. Specifically, the article states "increase [in heart disease] is proportional to the mean dose to the heart, begins within a few years after exposure, and continues for at least 20 years." During therapy the deep breath is actively monitored and when the patient begins to tire (which is visually noted to cross the threshold of heart avoidance and not possible to hold a deep breath for the entire treatment) the treatment is halted, the patient allowed to breath freely and take another deep breath and treatment is resumed. This is done repetitively until the full treatment is executed."

Prostate

"Use of a microboost to the dominant lesion seen on MRI, which on the FLAME trial showed substantial benefits for disease-free survival. FLAME mandated fiducial marker placement because of the high dose per fraction being delivered close to the urethra and rectum. I also recommend spaceOAR placement to protect the rectum while allowing for full dose escalation to the dominant lesion. ****We discussed the RCMIGI randomized trial showing intrafraction monitoring of prostate markers combined with reduced PTV margins resulted in less long-term urinary toxicity (PMID 41365376). I plan to use active motion monitoring of the prostate with triggered imaging of prostate markers and 3mm used as a beam-off threshold. ***This technology is medically necessary because of the close proximity of the urethra to the high dose microboost volume and proven efficacy in reducing urinary toxicity."

Noridian

Noridian has identified and is correcting a system error that was denying CPT 77387 for POS 19 and 22, with claim reprocessing expected in a few weeks.

UnitedHealthcare (UHC)

UHC’s revised RT guideline requires CPT 77387 to be billed with the -26 modifier starting March 1. For private payers still denying 77387 due to the modifier, ASTRO suggests resubmitting claims without it until there is payer consensus. Please check with individual payers on their policy on how to bill 77387 to avoid future denials. Members should continue to report inappropriate denials and payer issues .

EviCore

EviCore’s updated guideline should reduce high denial rates for CPT 77412. However, members should submit feedback to ASTRO if initial denials or the need for peer-to-peer calls does not decrease.

ASTRO and eviCore met to align on documentation expectations, and coding clarifications. The emphasis is on clear, concise documentation that supports medical necessity without adding administrative burden.

1. Active Motion Management Documentation (Including DIBH)

• eviCore is not looking for checkboxes alone or simply stating "DIBH."
• A brief sentence or twois sufficient if it clearly confirms:
  • The technology used (e.g., DIBH, AlignRT, surface guidance) or
  • Active motion management with defined thresholds that would pause the beam
• Templated language is strongly encouraged to improve consistency and reduce peer-to-peer calls.

2. Breast Cancer Guidelines

• Updated guidelines support billing 77412 for:
  • Active motion management during treatment delivery for left breast cancer for whole breast or postmastectomy radiation therapy.
  • Active motion management during treatment delivery for right breast cancer with internal mammary nodal irradiation.
  • Bilateral breast cancer when treatment is delivered concurrently to both breasts.
  • Multiple photon isocenters are required to deliver treatment to a long chest wall with an unusually large superior-inferior field length, exceeding standard single isocenter limits.
  • Concurrent use of mixed photon/electron fields for the breast boost.
• Comparison plans are not required.
• 77412 not currently approved for APBI. EviCore open to review on case-by-case basis if there is demonstrated clear heart dose being avoided with active motion management.

3. Multiple Isocenters

• ASTRO emphasized that CPT code description does not distinguish between malignant and non-malignant disease for treatment of multiple isos. EviCore expressed concern over abuse of 77412 cases without patient shifts or new setups, including adjacent treatment sites.
• There is a distinction in the AMA CPT language for codes 77402 and 77412, where 2D is not listed for multiple isocenters but is included in the CPT descriptor. EviCore denying 2D multiple iso cases for bone mets and osteoarthritis. ASTRO will be reaching out to AMA to clear this up to revisit for policy changes.
• EviCore looking for patient repositioning and reimaging time.
  • ASTRO countered with spine example, for example T10 and L2 lesions.

4. Image Guidance and Orthovoltage Coding

• The professional component of image guidance (77387) is approved for 2D, 3D, and IMRT treatments. No separate authorization required.
• Exception: superficial/orthovoltage treatments must use orthovoltage-specific codes (77436-77439) and cannot bill image guidance codes.
• This clarification is intended to reduce coding confusion and denials.

5. Prostate Treatment and Emerging Technologies

• Current policy does not approve 77412 for active motion management for prostate.
• eviCore is open to case-by-case review when clear clinical criteria, beam-off thresholds, and protocols are documented (e.g., MR-Linac, FLAME trial–based approaches).
• ASTRO will share supporting protocols and documentation to inform future guideline updates.